View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 13, 2019

ReGenTree begins ARISE-3 trial of RGN-259 for dry eye

Pharmaceutical firm ReGenTree has initiated a Phase III ARISE-3 clinical trial to evaluate drug candidate RGN-259 to treat patients with dry eye syndrome.

Pharmaceutical firm ReGenTree has initiated a Phase III ARISE-3 clinical trial to evaluate drug candidate RGN-259 to treat patients with dry eye syndrome.

RGN-259 is a sterile, preservative-free eye drop formulation. It had been previously evaluated in the ARISE-1 and ARISE-2 trials, which were conducted on approximately 300 and 600 patients respectively.

ReGenTree was established in 2015 as a joint venture (JV) between RegeneRx Biopharmaceuticals and G-treeBNT to develop RGN-259 for dry eye syndrome and neurotrophic keratitis in the US.

ARISE-3 is a randomised double-masked, placebo-controlled trial based on ARISE-1 and ARISE-2 data.

ReGenTree has signed an agreement with clinical research services provider Ora to conduct the trial.

“We are pleased that ReGenTree has initiated ARISE-3 and look forward to moving RGN-259 through the FDA regulatory process.”

It will involve a total of 700 participants, with treatment estimated to be completed by the first half of next year.

RegeneRx Biopharmaceuticals CEO JJ Finkelstein said: “We are pleased that ReGenTree has initiated ARISE-3 and look forward to moving RGN-259 through the FDA regulatory process, via ReGenTree or a partner, and into the market as soon as possible to treat this common disorder.”

The agreement will see G-treeBNT take responsibility for conducting and funding all clinical trials and product development through a new drug application (NDA) approval.

RegeneRx granted the JV an exclusive, royalty-bearing licence to market and sell RGN-259 in the US as part of the licencing agreement.

ReGenTree is also assessing RGN-259 in a 46-patient Phase III trial in neurotrophic keratopathy, where the product secured orphan drug designation from the US Food and Drug Administration (FDA).

RegeneRx has formed two alliances in Asia to develop the therapeutic for Asian patients with dry eye syndrome.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena